- Home
- EYPT vs AURA Comparison
EYPT vs AURA Comparison
Compare EYPT & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYPT
- AURA
- Stock Information
- Founded
- EYPT 1987
- AURA 2007
- Country
- EYPT United States
- AURA United States
- Employees
- EYPT N/A
- AURA N/A
- Industry
- EYPT Biotechnology: Laboratory Analytical Instruments
- AURA Biotechnology: Pharmaceutical Preparations
- Sector
- EYPT Industrials
- AURA Health Care
- Exchange
- EYPT Nasdaq
- AURA Nasdaq
- Market Cap
- EYPT 390.0M
- AURA 370.1M
- IPO Year
- EYPT 2005
- AURA 2021
- Fundamental
- Price
- EYPT $5.41
- AURA $4.91
- Analyst Decision
- EYPT Strong Buy
- AURA Strong Buy
- Analyst Count
- EYPT 7
- AURA 4
- Target Price
- EYPT $24.00
- AURA $22.75
- AVG Volume (30 Days)
- EYPT 610.5K
- AURA 180.9K
- Earning Date
- EYPT 05-07-2025
- AURA 05-20-2025
- Dividend Yield
- EYPT N/A
- AURA N/A
- EPS Growth
- EYPT N/A
- AURA N/A
- EPS
- EYPT N/A
- AURA N/A
- Revenue
- EYPT $56,042,000.00
- AURA N/A
- Revenue This Year
- EYPT N/A
- AURA N/A
- Revenue Next Year
- EYPT N/A
- AURA N/A
- P/E Ratio
- EYPT N/A
- AURA N/A
- Revenue Growth
- EYPT 12.04
- AURA N/A
- 52 Week Low
- EYPT $3.91
- AURA $4.84
- 52 Week High
- EYPT $21.26
- AURA $12.38
- Technical
- Relative Strength Index (RSI)
- EYPT 43.45
- AURA 42.47
- Support Level
- EYPT $5.75
- AURA $4.96
- Resistance Level
- EYPT $6.29
- AURA $5.92
- Average True Range (ATR)
- EYPT 0.47
- AURA 0.46
- MACD
- EYPT -0.11
- AURA -0.01
- Stochastic Oscillator
- EYPT 0.00
- AURA 16.67
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.